There are currently 41 ongoing clinical trials involving Leptomeningeal Disease (Neoplastic Meningitis, Leptomeningeal Carcinomatosis)
Of the 41 trials,16 trials are in Phase I
Furthermore, 14 trials are in Phase II
The global pharmaceutical industry is steadily developing new drugs for Leptomeningeal Disease, an Oncology disorder. The largest number of ongoing clinical trials for Leptomeningeal Disease is conducted in North America. Europe and Asia-Pacific are among some of the other prominent regions engaged in Leptomeningeal Disease-related drug trials.
Leptomeningeal Disease-related clinical trials sponsors
Memorial Sloan Kettering Cancer Center, University of Texas MD Anderson Cancer Center, Massachusetts General Hospital, City of Hope, and Dana-Farber/Harvard Cancer Center are a few notable clinical trial sponsors involved in Leptomeningeal Disease. A clinical trial sponsor can be a Company, Government, Individual, or Institution.
Marketed Drugs involving Leptomeningeal Disease
Asparaginase (Kidrolase), Cytarabine (DepoCyt / DepoCyte), and Methotrexate are among the key marketed drugs involving Leptomeningeal Disease.
Asparaginase (Kidrolase) is an enzyme isolated from Escherichia coli that acts as an antileukemic agent. It functions via the Asparagine Depletor mechanism of action. It is formulated as powder for solution for intramuscular or intravenous route of administration. Kidrolase is indicated mainly to induce remissions in acute lymphoblastic leukemia and remissions have also been obtained in cases of acute myeloblastic and acute myelomonocytic leukemia although these forms are less sensitive to the action of the enzyme. It is indicated in the treatment of meningitis leukemia and non-Hodgkin lymphoma. Asparaginase was first approved in 1997 and is marketed in Canada, France, and Israel by Jazz Pharmaceuticals Plc.
Cytarabine (DepoCyt / DepoCyte) is a pyrimidine nucleoside analog that belongs to an antineoplastic class, encapsulated into multivesicular lipid-based particles. It functions via DNA Polymerase Inhibitor, DNA Synthesis Inhibitor mechanism of action. It is formulated as liposomal injectable suspension for intrathecal administration. Depocyt is indicated for the treatment of lymphomatous meningitis. Cytarabine was first approved in 1999 and is marketed globally including in the US, the UK, Australia, France, and Germany by Leadiant Biosciences Inc.
United States of America
China
Switzerland
United States of America
United States of America
United States of America
United States of America
Germany
France
Switzerland
Don’t wait - discover a universe of connected data & insights with your next search. Browse over 28M data points across 22 industries.
Access more premium companies when you subscribe to Explorer
Contact the team or request a demo to find out how our data can drive your business forward